347 related articles for article (PubMed ID: 17251257)
1. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
[TBL] [Abstract][Full Text] [Related]
2. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study.
Admiral Investigators
Eur Heart J; 2005 Dec; 26(23):2520-3. PubMed ID: 16249219
[TBL] [Abstract][Full Text] [Related]
3. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.
Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL
Catheter Cardiovasc Interv; 2010 May; 75(6):895-902. PubMed ID: 20088008
[TBL] [Abstract][Full Text] [Related]
4. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.
Navarese EP; Kozinski M; Obonska K; Margheri M; Gurbel PA; Kubica J; De Luca G
Platelets; 2012; 23(4):274-81. PubMed ID: 21988317
[TBL] [Abstract][Full Text] [Related]
6. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
Tornvall P; Nilsson T; Lagerqvist B
J Intern Med; 2006 Oct; 260(4):363-8. PubMed ID: 16961673
[TBL] [Abstract][Full Text] [Related]
7. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
[TBL] [Abstract][Full Text] [Related]
8. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of early abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: results of the REO-SHOCK trial.
Zeymer U; Tebbe U; Weber M; Vohringer HF; Jaksch R; Bischoff KO; Toepel W; Marsalek P; Horn S; Neuhaus KL;
J Invasive Cardiol; 2003 Jul; 15(7):385-9. PubMed ID: 12840235
[TBL] [Abstract][Full Text] [Related]
11. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
12. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB
Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536
[TBL] [Abstract][Full Text] [Related]
13. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).
Cox DA; Stone GW; Grines CL; Stuckey T; Zimetbaum PJ; Tcheng JE; Turco M; Garcia E; Guagliumi G; Iwaoka RS; Mehran R; O'Neill WW; Lansky AJ; Griffin JJ;
Am J Cardiol; 2006 Aug; 98(3):331-7. PubMed ID: 16860018
[TBL] [Abstract][Full Text] [Related]
14. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
[TBL] [Abstract][Full Text] [Related]
15. Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction.
De Luca G; Suryapranata H; Grimaldi R; Chiariello M
QJM; 2005 Sep; 98(9):633-41. PubMed ID: 16040669
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting.
Ndrepepa G; Kastrati A; Neumann FJ; Schmitt C; Mehilli J; Schömig A
Eur Heart J; 2004 Sep; 25(18):1635-40. PubMed ID: 15351163
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ;
Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016
[TBL] [Abstract][Full Text] [Related]
19. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention.
Huang R; Sacks J; Thai H; Goldman S; Morrison DA; Barbiere C; Ohm J
Catheter Cardiovasc Interv; 2005 May; 65(1):25-33. PubMed ID: 15800889
[TBL] [Abstract][Full Text] [Related]
20. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Van de Werf F; Antman EM; Topol EJ
JAMA; 2005 Apr; 293(14):1759-65. PubMed ID: 15827315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
